Changes in Circulating Kisspeptin Levels During Each Trimester in Women With Antenatal Complications
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society..
CONTEXT: Antenatal complications such as hypertensive disorders of pregnancy (HDP), fetal growth restriction (FGR), gestational diabetes (GDM), and preterm birth (PTB) are associated with placental dysfunction. Kisspeptin has emerged as a putative marker of placental function, but limited data exist describing circulating kisspeptin levels across all 3 trimesters in women with antenatal complications.
OBJECTIVE: We aimed to assess whether kisspeptin levels are altered in women with antenatal complications.
METHODS: Women with antenatal complications (n = 105) and those with uncomplicated pregnancies (n = 265) underwent serial ultrasound scans and blood sampling at the Early Pregnancy Assessment Unit at Hammersmith Hospital, UK, at least once during each trimester (March 2014 to March 2017). The women with antenatal complications (HDP [n = 32], FGR [n = 17], GDM [n = 35], PTB [n = 11], and multiple complications [n=10]) provided 373 blood samples and the controls provided 930 samples. Differences in circulating kisspeptin levels were assessed.
RESULTS: Third-trimester kisspeptin levels were higher than controls in HDP but lower in FGR. The odds of HDP adjusted for gestational age, maternal age, ethnicity, BMI, smoking, and parity were increased by 30% (95% CI, 16%-47%; P < 0.0001), and of FGR were reduced by 28% (95% CI, 4-46%; P = 0.025), for every 1 nmol/L increase in plasma kisspeptin. Multiple of gestation-specific median values of kisspeptin were higher in pregnancies affected by PTB (P = 0.014) and lower in those with GDM (P = 0.020), but not significantly on multivariable analysis.
CONCLUSION: We delineate changes in circulating kisspeptin levels at different trimesters and evaluate the potential of kisspeptin as a biomarker for antenatal complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 107(2022), 1 vom: 01. Jan., Seite e71-e83 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abbara, Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2022 Date Revised 14.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgab617 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329709119 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329709119 | ||
| 003 | DE-627 | ||
| 005 | 20231225205712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgab617 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329709119 | ||
| 035 | |a (NLM)34427658 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abbara, Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Changes in Circulating Kisspeptin Levels During Each Trimester in Women With Antenatal Complications |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2022 | ||
| 500 | |a Date Revised 14.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a CONTEXT: Antenatal complications such as hypertensive disorders of pregnancy (HDP), fetal growth restriction (FGR), gestational diabetes (GDM), and preterm birth (PTB) are associated with placental dysfunction. Kisspeptin has emerged as a putative marker of placental function, but limited data exist describing circulating kisspeptin levels across all 3 trimesters in women with antenatal complications | ||
| 520 | |a OBJECTIVE: We aimed to assess whether kisspeptin levels are altered in women with antenatal complications | ||
| 520 | |a METHODS: Women with antenatal complications (n = 105) and those with uncomplicated pregnancies (n = 265) underwent serial ultrasound scans and blood sampling at the Early Pregnancy Assessment Unit at Hammersmith Hospital, UK, at least once during each trimester (March 2014 to March 2017). The women with antenatal complications (HDP [n = 32], FGR [n = 17], GDM [n = 35], PTB [n = 11], and multiple complications [n=10]) provided 373 blood samples and the controls provided 930 samples. Differences in circulating kisspeptin levels were assessed | ||
| 520 | |a RESULTS: Third-trimester kisspeptin levels were higher than controls in HDP but lower in FGR. The odds of HDP adjusted for gestational age, maternal age, ethnicity, BMI, smoking, and parity were increased by 30% (95% CI, 16%-47%; P < 0.0001), and of FGR were reduced by 28% (95% CI, 4-46%; P = 0.025), for every 1 nmol/L increase in plasma kisspeptin. Multiple of gestation-specific median values of kisspeptin were higher in pregnancies affected by PTB (P = 0.014) and lower in those with GDM (P = 0.020), but not significantly on multivariable analysis | ||
| 520 | |a CONCLUSION: We delineate changes in circulating kisspeptin levels at different trimesters and evaluate the potential of kisspeptin as a biomarker for antenatal complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a fetal growth restriction (FGR) | |
| 650 | 4 | |a gestational diabetes (GDM) | |
| 650 | 4 | |a hypertensive diseases of pregnancy (HDP) | |
| 650 | 4 | |a intrauterine growth restriction (IUGR) | |
| 650 | 4 | |a kisspeptin | |
| 650 | 4 | |a preterm birth (PTB) | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Kisspeptins |2 NLM | |
| 700 | 1 | |a Al-Memar, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Phylactou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Daniels, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Bijal |e verfasserin |4 aut | |
| 700 | 1 | |a Eng, Pei C |e verfasserin |4 aut | |
| 700 | 1 | |a Nadir, Rans |e verfasserin |4 aut | |
| 700 | 1 | |a Izzi-Engbeaya, Chioma |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Sophie A |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Edouard G |e verfasserin |4 aut | |
| 700 | 1 | |a Hunjan, Tia |e verfasserin |4 aut | |
| 700 | 1 | |a Pacuszka, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bech, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Tricia |e verfasserin |4 aut | |
| 700 | 1 | |a Comninos, Alexander N |e verfasserin |4 aut | |
| 700 | 1 | |a Kelsey, Tom W |e verfasserin |4 aut | |
| 700 | 1 | |a Kyriacou, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Fourie, Hanine |e verfasserin |4 aut | |
| 700 | 1 | |a Bourne, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Dhillo, Waljit S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 107(2022), 1 vom: 01. Jan., Seite e71-e83 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:e71-e83 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgab617 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2022 |e 1 |b 01 |c 01 |h e71-e83 | ||